NASDAQ:XERS - Xeris Pharmaceuticals Stock Price, Forecast & News

Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."

Xeris Pharmaceuticals Inc (NASDAQ:XERS) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($1.22) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.23) by $0.01. The business had revenue of $0.32 million for the quarter, compared to analysts' expectations of $0.20 million. Xeris Pharmaceuticals had a negative net margin of 6,697.33% and a negative return on equity of 150.08%. View Xeris Pharmaceuticals' Earnings History.

Xeris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Xeris Pharmaceuticals.

3 Wall Street analysts have issued 1 year price targets for Xeris Pharmaceuticals' shares. Their forecasts range from $12.00 to $22.00. On average, they anticipate Xeris Pharmaceuticals' share price to reach $17.33 in the next twelve months. This suggests a possible upside of 268.4% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals.

Media coverage about XERS stock has been trending neutral this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Xeris Pharmaceuticals earned a daily sentiment score of 0.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Xeris Pharmaceuticals.

Some companies that are related to Xeris Pharmaceuticals include Dynavax Technologies (DVAX), ProQR Therapeutics (PRQR), Recro Pharma (REPH), Cue Biopharma (CUE), AnaptysBio (ANAB), Avid Bioservices (CDMO), Avedro (AVDR), Calithera Biosciences (CALA), Mallinckrodt (MNK), Progenics Pharmaceuticals (PGNX), Mirum Pharmaceuticals (MIRM), DURECT (DRRX), Galera Therapeutics (GRTX), Verrica Pharmaceuticals (VRCA) and Rigel Pharmaceuticals (RIGL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN), AbbVie (ABBV), ADMA Biologics (ADMA), Agile Therapeutics (AGRX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Kala Pharmaceuticals (KALA), Omeros (OMER) and Strongbridge Biopharma (SBBP).

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager.

Xeris Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Citigroup Inc. (8.15%), ArrowMark Colorado Holdings LLC (7.14%), State Street Corp (1.85%), Blackstone Group Inc (1.67%), IHT Wealth Management LLC (0.34%) and Bank of New York Mellon Corp (0.31%). Company insiders that own Xeris Pharmaceuticals stock include Beth Hecht, James E Flynn, John Patrick Shannon Jr, Palmetto Partners, Ltd, Paul R Edick, Redmile Group, Llc and Steven Prestrelski. View Institutional Ownership Trends for Xeris Pharmaceuticals.

XERS stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Goldman Sachs Group Inc. and Bank of America Corp DE. View Insider Buying and Selling for Xeris Pharmaceuticals.

XERS stock was purchased by a variety of institutional investors in the last quarter, including Citigroup Inc., Blackstone Group Inc, ArrowMark Colorado Holdings LLC, California Public Employees Retirement System, State Street Corp, IHT Wealth Management LLC, Marshall Wace LLP and Marshall Wace North America L.P.. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include Beth Hecht, James E Flynn, John Patrick Shannon Jr, Palmetto Partners, Ltd, Paul R Edick and Redmile Group, Llc. View Insider Buying and Selling for Xeris Pharmaceuticals.

Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XERS stock can currently be purchased for approximately $4.71.

Xeris Pharmaceuticals has a market capitalization of $127.01 million and generates $2.46 million in revenue each year. The company earns $-60,080,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Xeris Pharmaceuticals employs 90 workers across the globe.View Additional Information About Xeris Pharmaceuticals.

The official website for Xeris Pharmaceuticals is http://www.xerispharma.com/.

Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected]